Search

1 to 10 of 627
Sort by

Library Entry
Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article investigating the immunological effects of metabolic stress in cancer cells as a result of nutrient deprivation. Authors: Koen A. Marijt , Marjolein Sluijter , Laura Blijleven , Sofie H. Tolmeijer , Ferenc A...


Library Entry
PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8+ T lymphocytes

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article suggesting that mitochondria are the main targets of PD-1 inhibitory activity. PD-1 reprograms CD8 + T cell metabolism for efficient use of fatty acid oxidation; this mitochondrial phenotype might explain the...


Library Entry
Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article in which an immunocytokine, NHS-muIL12, which consists of two molecules of murine IL-12 fused to NHS76, a tumor necrosis-targeting human IgG1, was examined as an immunotherapeutic in an orthotopic MB49 luc ...


Library Entry
CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article demonstrating that high numbers of peripheral CD8 T cells expressing differentiation markers and lacking co-stimulatory receptors at baseline are associated with response to nivolumab in NSCLC patients. Authors: ...


Library Entry
DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article providing evidence for co-expression of multiple immune checkpoint genes including, PD-1 , PD-L1, IDO1, TIGIT, TIM-3, TGFB1, LAG3, and others, that potentially contribute to compensatory immune evasion in...


Library Entry
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a short report on the final planned analysis of OPTiM, a randomized open-label phase III trial of T-vec in patients with unresectable stage IIIB–IVM1c melanoma. Authors: Robert H. I. Andtbacka , Frances Collichio , Kevin J....


Library Entry
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report discussing immuno-PET studies of PD-L1 in a preclinical tumorgraft model of clear cell RCC (ccRCC) from a patient who had a favorable response to anti-PD-1 therapy. Authors: Joseph Vento , Aditi Mulgaonkar , ...


Library Entry
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article reporting the results of a phase I study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of weekly ONC201. Authors: Mark N. Stein , Jyoti Malhotra , Rohinton S. Tarapore , Usha...


Library Entry
Level of neo-epitope predecessor and mutation type determine T cell activation of MHC binding peptides

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article which analyzed several experimental datasets from cancer patients to elaborate better predictive algorithms for T-cell reactivity to neo-epitopes. Authors: Hanan Besser , Sharon Yunger , Efrat Merhavi-Shoham ,...


Library Entry
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report describing a patient with myasthenia gravis treated with pembrolizumab demonstrating successful outcomes. Authors: Anne Zaremba , Eleftheria Chorti , Finja Jockenhöfer , Saskia Bolz , Selma Sirin , Martin Glas ,...